PMID- 24140772
OWN - NLM
STAT- MEDLINE
DCOM- 20150402
LR  - 20211021
IS  - 1349-8029 (Electronic)
IS  - 0470-8105 (Print)
IS  - 0470-8105 (Linking)
VI  - 53
IP  - 11
DP  - 2013
TI  - Dendritic cell-based immunotherapy for glioma: multiple regimens and implications 
      in clinical trials.
PG  - 741-54
AB  - High grade glioma is a highly invasive brain tumor and recurrence is almost 
      inevitable, even after radical resection of the tumor mass. Cytotoxic immune 
      responses and immunological memory induced by immunotherapy might prevent tumor 
      recurrence. Dendritic cells (DCs) are professional antigen-presenting cells of 
      the innate immune system with the potential to generate robust antigen-specific T 
      cell immune responses. DC-based immunotherapeutic strategies have been 
      intensively studied in both preclinical and clinical settings. Although advances 
      have been made in the experimental use of DCs, there are still considerable 
      challenges that need to be addressed for clinical translation. In this review, we 
      describe the variability of regimens currently available for DC-based 
      immunotherapy and then review strategies to optimize DC therapeutic efficacy 
      against glioma.
FAU - Mineharu, Yohei
AU  - Mineharu Y
AD  - Division of Neuroendovascular Therapy, Institute of Biomedical Research and 
      Innovation.
FAU - Castro, Maria G
AU  - Castro MG
FAU - Lowenstein, Pedro R
AU  - Lowenstein PR
FAU - Sakai, Nobuyuki
AU  - Sakai N
FAU - Miyamoto, Susumu
AU  - Miyamoto S
LA  - eng
GR  - R01 NS054193/NS/NINDS NIH HHS/United States
GR  - R01 NS082311/NS/NINDS NIH HHS/United States
GR  - R21 NS047298/NS/NINDS NIH HHS/United States
GR  - R01 NS074387/NS/NINDS NIH HHS/United States
GR  - U01 NS052465/NS/NINDS NIH HHS/United States
GR  - R01 NS061107/NS/NINDS NIH HHS/United States
GR  - U54 NS045309/NS/NINDS NIH HHS/United States
GR  - R21 NS084275/NS/NINDS NIH HHS/United States
GR  - R01 NS042893/NS/NINDS NIH HHS/United States
GR  - R01 NS057711/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20131021
PL  - Japan
TA  - Neurol Med Chir (Tokyo)
JT  - Neurologia medico-chirurgica
JID - 0400775
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cytokines)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/genetics/immunology
MH  - Autophagy
MH  - Bone Marrow Cells/drug effects
MH  - Brain Neoplasms/*therapy
MH  - Cell Differentiation/drug effects
MH  - Clinical Trials as Topic
MH  - Cytokines/physiology
MH  - Dendritic Cells/classification/immunology/*transplantation
MH  - Glioma/*therapy
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Models, Immunological
MH  - Phagosomes
MH  - T-Lymphocytes, Cytotoxic/immunology
PMC - PMC3926207
MID - NIHMS551010
COIS- Conflicts of Interest Disclosure There is no COI to be disclosed.
EDAT- 2013/10/22 06:00
MHDA- 2015/04/04 06:00
PMCR- 2013/11/01
CRDT- 2013/10/22 06:00
PHST- 2013/10/22 06:00 [entrez]
PHST- 2013/10/22 06:00 [pubmed]
PHST- 2015/04/04 06:00 [medline]
PHST- 2013/11/01 00:00 [pmc-release]
AID - DN/JST.JSTAGE/nmc/ra2013-0234 [pii]
AID - nmc-53-741 [pii]
AID - 10.2176/nmc.ra2013-0234 [doi]
PST - ppublish
SO  - Neurol Med Chir (Tokyo). 2013;53(11):741-54. doi: 10.2176/nmc.ra2013-0234. Epub 
      2013 Oct 21.